Research and development daily Junshi PD-1 combination therapy first-line advanced hepatocellular carcinoma phase III clinical start.

The results of the Pfizer/BioNTech new crown vaccine Phase 1/2 were positive; the Johnson and Johnson Ebola Vaccine Program was approved by the European Union; Amgen/Baiji Shenzhou CD3/CLDN18.2 bispecific antibodies were declared clinicalin in China; and The Hang Seng JAK1 inhibitors were approved for clinical trials of vitiligoWe focus on the latest developments in pharmaceutical research and development, to provide research and development personnel with timely and accurate information reference, Pfizer and BioNTech announced that their new mRNA-based coronavirus vaccine has achieved positive results in Phase 1/2 clinical trialsChina-Led Pharmaceuticals recently announced the positive results of its 24-week core clinical study of the world's first new drug, glucose kinase activator dorzagliatin, and metformin (global first-line drug for type 2 diabetes)on1, Junshi registered to launch a clinical study of Tripri sing-in-combination runitatinib single drug-type treatment of advanced liver cell cancer for prospective randomized controlled double-blind multi-center III, Akero Therapeutics incannounced an analysis of its treatment for NASH in the middle term of the research therapy eluxiferminOf the 40 patients who received tissue biopsies after treatment, 48% achieved at least one level of improvement in liver fibrosis and at least two levels of fibrosis in the absence of a deterioration in the activity score of non-alcoholic fatty liver diseaseBaiji Shenzhou today announced that the NMPA Drug Review Center has accepted its application for the market of the anti-PD-1 antibody drug Bacaan ® (Trelizumab antist injection) for the treatment of previously treated patients with non-removable hepatocellular cancer (HCC)On1, Johnson and Johnson announced that its Johnson Pharmaceuticals' Dual Measurement Package for the Ebola Vaccine, Zabdeno ® (Ad26.ZEBOV) and mvabea ® (MVaBN Filo), had been approved by the European Commission for the use of active immunization to prevent Ebola virus infection in individuals aged 1 and over caused by the Ebola virus in the Democratic Republic of the Congo1, according to CDE official website, Yuxi Zerun Biotechnology Co., Ltdreorganized human papillomavirus double price (16/18 type) vaccine (yeast) listing application was accepted, which means that the second domestic two-price HPV vaccine reported production, domestic HPV vaccine is expected to usher in a new spoilerOn1, the AMG 910 clinical application submitted by Amjin/Baiji Shenzhou was accepted by CDEThe drug is currently in the clinical phase of stage I of gastric cancer or gastric esophagus cancer worldwide2, Hengrui announced that its class 1 new drug SHR0302 alkali ointment approved for vitiligo clinical trialon2, China Biopharma announced that its subsidiary Nanjing Zhengda Tianqing 4 class of generic drug sulphate clopidogrel tablets were approved by the State Drug Administration for listing, as the same as through the consistency evaluation, as the fourth domesticOn1, the clinical application of the recombinant human tumor necrosis-related apoptosis-tripolymer fusion protein (CB-313) for the injection of a new class 1 drug in Sichuan sane clover was accepted by CDErecently, the official website of the State Drug Administration shows that the linamine injection of Bo Dawei pharmaceutical in Jilin Province was approved for production, making it the 8th domesticToday, a new paper published in Nature describes a new small molecule drug developed by the biopharmaceutical company Gilead Sciences, demonstrating the potential for long-term treatment of HIV infectionPreliminary clinical studies showed that hiv-infected people were injected with this drug in a single dose, the body of the virus load decreased, and the drug was injected in six.